M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

M-TEER Benefits in Secondary Mitral Regurgitation: Consistent Clinical and Quality-of-Life Improvements Regardless of Baseline Health Status

The RESHAPE-HF2 trial reveals that mitral transcatheter edge-to-edge repair (M-TEER) significantly reduces cardiovascular risks and enhances health status across all baseline patient conditions, reinforcing its role as a key intervention for symptomatic heart failure and secondary mitral regurgitation.
The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality

The Price of Time: 20-Year Study Reveals Pre-Hospital Delay as a Critical Driver of STEMI Mortality

A 20-year analysis of 89,155 patients from the SWEDEHEART registry confirms that pre-hospital delay independently predicts short- and long-term mortality. Despite advances in reperfusion, women, elderly patients, and those with diabetes consistently experience significantly longer delays, highlighting a critical need for targeted public health interventions.